0001104659-21-110526.txt : 20210827
0001104659-21-110526.hdr.sgml : 20210827
20210827161002
ACCESSION NUMBER: 0001104659-21-110526
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210826
FILED AS OF DATE: 20210827
DATE AS OF CHANGE: 20210827
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lawson Jeffrey Harold
CENTRAL INDEX KEY: 0001879530
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39532
FILM NUMBER: 211218998
MAIL ADDRESS:
STREET 1: 4203 COBSCOOK DR.
CITY: DURHAM
STATE: NC
ZIP: 27707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Humacyte, Inc.
CENTRAL INDEX KEY: 0001818382
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 851763759
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919-313-9633
MAIL ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
FORMER COMPANY:
FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp.
DATE OF NAME CHANGE: 20200716
4
1
tm2125954-17_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-08-26
0
0001818382
Humacyte, Inc.
HUMA
0001879530
Lawson Jeffrey Harold
2525 EAST NORTH CAROLINA HIGHWAY 54
DURHAM
NC
27713
1
1
0
0
Chief Surgical Officer
Common Stock
2021-08-26
4
A
0
7877
A
7877
D
Stock Options (right to buy)
2.56
2021-08-26
4
A
0
90595
A
2025-12-11
Common Stock
90595
90595
D
Stock Options (right to buy)
3.44
2021-08-26
4
A
0
65649
A
2026-12-15
Common Stock
65649
65649
D
Stock Options (right to buy)
6.54
2021-08-26
4
A
0
118168
A
2028-04-12
Common Stock
118168
118168
D
Stock Options (right to buy)
8.48
2021-08-26
4
A
0
1194815
A
2028-06-28
Common Stock
1194815
1194815
D
Stock Options (right to buy)
10.28
2021-08-26
4
A
0
1575
A
2021-12-14
2030-12-14
Common Stock
1575
1575
D
On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
Options are fully vested and exercisable.
As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.
/s/ Jeffrey Harold Lawson by Dale A. Sander as Attorney-in-Fact
2021-08-27